Notice: Release of Draft (Step 2) ICH Guidance: M7 Addendum - Assessment and Control of DNA Reactive (Mutagenic) Impurities in Pharmaceuticals to Limit Potential Carcinogenic Risk
Notice to the reader:The online consultation is now closed. The final guidance is available now.
The above referenced draft guidance was released by the ICH Steering Committee for consultation and is being posted on the Health Canada website for information and comment in accordance with Step 2 of the ICH process.
How to Get Involved
This consultation is open for comment starting July 30 until October 28, 2015. Please select and read through the link below titled "consultation document". Once read, please submit your comments via email, fax or by mail to:
Bureau of Metabolism, Oncology and Reproductive Sciences
Therapeutic Products Directorate
Health Products and Food Branch
1600 Scott St, Holland Cross
Interested parties are encouraged to provide comments and suggestions by October 28, 2015.
Reporting to Canadians
Health Canada will make the results of this consultation available on this Web site.
If you have any questions, contact Alisa Vespa.
Report a problem or mistake on this page
- Date modified: